Messages about Clinical Research and Trials

In this closing message to the 75th-Anniversary series, Acting NIMH Director Shelli Avenevoli reflects on a year of celebration and the future of mental health research.

Small businesses are often at the forefront of innovative science, developing new technologies that push mental health research into the future. Learn how NIMH supports small business research through its Small Business Innovation Research Program and Small Business Technology Transfer Program.

In this Director’s Message, Dr. Gordon highlights research supported by the NIMH Small Business Innovation Research program that could advance the development of clinically relevant biomarkers.

In this message for National Eating Disorder Awareness Week, Dr. Gordon highlights NIMH-funded research aimed at reducing the impact of eating disorders.

In this message, Dr. Gordon highlights a new public-private partnership that aims to develop novel treatment approaches that will make a meaningful difference in the lives of individuals at risk of schizophrenia.

This week, the National Institute of Mental Health unveiled its new NIMH Strategic Plan for Research. In this Director’s message, Dr. Gordon discusses the advances in knowledge and treatment that got us to where we are today and points to where we want our research to go in the future.

Mental health disparities are significant and easily documented. In this Director’s Message, Dr. Gordon discusses NIMH-funded research that aims to close the gap, ensuring that improved mental health care meets the needs of all Americans.

In this Director’s Message, Dr. Gordon discusses the potential that technology holds for expanding the reach of mental health care.

In his latest message, Dr. Gordon discusses the role of NIMH and other researchers in the development of esketamine, an FDA-approved, rapid-acting medication that targets treatment-resistant depression.

In this message, Dr. Gordon discusses the role of NIMH and others in the bench-to-bedside story of brexanolone, which has just been approved by the FDA as the first treatment specifically for postpartum depression.

Dr. Gordon offers highlights of his summer reading in science and literature.

Dr. Gordon talks about NIMH’s commitment to support the development and testing of psychosocial interventions in the greater context of the experimental therapeutics approach to treatment research.